Business
Cassowary Capital Corporation Limited Announces Letter of Intent to Complete a Qualifying Transaction with Lobo Genetics Inc.
Cassowary Capital Corporation Limited Announces Letter of Intent to Complete a Qualifying ...
About this update from Western Gold Exploration Ltd.
[{"type":"text","content":"\n\n\n\nCassowary Capital Corporation Limited Announces Letter of Intent to Complete a Qualifying Transaction with Lobo Genetics Inc.\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, Nov. 22, 2018\n\n\n\n/NOT FOR DISTRIBUTION OR FOR DISSEMINATION IN THE UNITED STATES/\n TORONTO, Nov. 22, 2018 /CNW/ - Cassowary Capital Corporation Limited (TSXV: BIRD.P) (\"BIRD\") is pleased to announce that it has entered into a non-binding letter of intent (the \"LOI\") with Lobo Genetics Inc. (\"Lobo\", and together with BIRD, the \"Parties\") dated November 20, 2018, pursuant to which the Parties will complete a transaction that will result in a reverse takeover of BIRD by Lobo (the \"Acquisition\").\nBIRD is a Capital Pool Company as defined in the policies of the TSX Venture Exchange (the \"Exchange\"), and intends for the Acquisition to constitute its Qualifying Transaction (as such term is defined in the policies of the Exchange). The Resulting Issuer (as such term is defined in the policies of the Exchange) intends to list as a Tier 2 Technology Issuer, subject to meeting the Initial Listing Requirements of the Exchange following the Qualifying Transaction.\nAbout Lobo Genetics Inc.Lobo is a privately-held healthcare technology company that was incorporated under the Canada Business Corporations Act on June 11, 2018 and has been engaged in its business continuously since incorporation. \nLobo helps ensure a safer cannabis experience through genetics. Consumers and patients can gain rapid, actionable insights into their personal response to cannabis, based on their genetic profile. Lobo's portable Cube DNA platform (the \"Cube\") tests an individual's DNA for genetic markers related to cannabis metabolism, risk and impairment: (a) reduced ability to metabolize THC and CBD; (b) increased acute psychotomimetic effects and long-term risk of cannabis-induced psychosis; and (c) neurocognitive impairment including short-term memory loss. Test samples are collected using a simple, non-invasive cheek swab. The Cube requ...